As an alternative approach, we employed the thalidomide derivative lenalidomide, which has been shown to induce the proteasomal degradation of IKZF3 (and IKZF1) and is used therapeutically in treating multiple myeloma (28–30). Here, IKZF3 is linked to plasma cell myeloma.